👏👏👏

🧬 In prostate cancer, not all #HRR alterations are equal. In this European Urology editorial, Elena Castro, Olmos & Lorente dissect the nuanced response to #PARP inhibitors—highlighting gene-specific efficacy, regulatory discord between FDA & EMA, and future challenges. 📖 Read:

David Olmos David Lorente

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

Happy to talk about BRCA2 mut in prostate cancer at the British Association of Urological Surgeons #BAUS25 In Manchester! Great vibes 💪🏻

🧬 ¿BRCA en próstata? El volumen ya no es lo más importante. El estudio CAPTURE, liderado por David Olmos y Elena Castro desde el Hospital 12 de Octubre, demuestra que las mutaciones en BRCA1/2 empeoran el pronóstico en cáncer de próstata, independientemente del volumen

Back from an inspiring #ESMOGynae25 🇦🇹 Fantastic opportunity to learn from 🔝 faculty & Network Honoured to receive the #BestPoster award Hospital Universitario 12 de Octubre & share an #ADC session with Philip Harter & Christian Marth

Un placer compartir junto a David Olmos⁩ este reconocimiento de ⁦Gaceta Médica⁩ sobre nuestro proyecto #capture ⁦Hospital Universitario 12 de Octubre⁩ ⁦Hospital Clínico Virgen de la Victoria⁩ ⁦IBIMA Plataforma BIONAND⁩ Consejería de Salud y Consumo recordando la importancia del diagnostico molecular en ca de prostata gacetamedica.com/investigacion/…

🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should include genomics. Congratulations David and all team. 👏👏👏 David Olmos Elena Castro Daniel Castellano Annals of Oncology Tom Powles Advanced Prostate Cancer Consensus Conference OncoAlert

📢 NEW in European Urology by Johann S. de Bono et al. 🧬 Final OS results from the phase 3 IPATential150 trial: ❌ No OS benefit from adding ipatasertib to abiraterone in mCRPC with PTEN loss (by IHC) 🔍 Exploratory NGS suggests AKT pathway alterations (PIK3CA/AKT1/PTEN, RTK)

+10 años liderando desde España la generación de conocimiento del papel de #BRCA1 #BRCA2 y otros genes de #HRR en #Cancer #próstata así como al desarrollo de #PARPi en esta enfermedad. Pero a día de hoy misión imposible Dx y tratar adecuadamente a estos pacientes en nuestro SNS

p-value decoding guide: 0.0000000001 Nobel 🥇 0.049 🍾 0.050 😬 redo math 0.06 “Trending toward…” 0.08 p < 0.10? Why not? ≥0.1 Time for subgroup magic! Keith Siau

Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations. Read the opinion by Elena Castro in the #ESMODailyReporter 🔗 ow.ly/4kOC50WfVTQ #ProstateCancer #mHSPC #PersonalisedMedicine

Another trial pointing at MMR defects as biomarker of ICI sensitivity in prostate cancer. Read ⬇️ NIHR Royal Marsden BRC with @ICRLondon and CRF Lolín Fenor Adam Sharp thank you to all the ICR team and Prof De Bono for this 💪🏻

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer Nature Communications rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab Dana-Farber Lank Center for Genitourinary Oncology PCF Science

Felix y agradecido a la AEU por la eleccion de nuestro querido estudio #Capture IBIMA Plataforma BIONAND Hospital Clínico Virgen de la Victoria Hospital Universitario 12 de Octubre con el premio a la mejor comunicacion en el Congreso Nacional de Urologia 2025 Un estudio academico español que demuestra por primera vez la importancia de las

🔥Can we predict relapse in colon cancer before surgery❓Together with HMar Research Institute and Quibim, we built an AI-radiomics model that identifies high-risk patients from pre-op CT scans. 📌Published in ESMO Open 🔗sciencedirect.com/science/articl…

Our last paper in Annals of Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater impact in low volume😯. Doublets with ARPi or docetaxel result in comparable poor outcomes for BRCA pts annalsofoncology.org/article/S0923-…

Elena Castro Annals of Oncology This is an intriguing finding, Elena! It raises questions about whether treatment strategies should be more bespoke for mHSPC patients with BRCA mutations. Are there any hypotheses on why these mutations show a greater impact in low volume disease? Could personalized medicine

Datos de mutaciones BRCA y HRR en #prostatecancer hormonos sensible 🧑‍🤝‍🧑 mut HRR & BRCA similres en alto & bajo volumen 📢 El impacto de BRCA/HRR parece mayor el bajo volumen ⚠️Paciente con alt-BRCA tiene peeores resutaldos con dupletes (ACT+ARSI o ADT + Docetaxel)